Abstract
Depression is a common co-morbidity in patients with cardiovascular diseases such as chronic coronary artery disease, acute coronary syndromes, post by-pass surgery and chronic heart failure. The presence of depression is independently associated with a decline in health status and an increase in the risk of hospitalization and death for patients with coronary artery disease or congestive heart failure. Novel treatment modalities such as selective serotonin re-uptake inhibitors (SSRIs) may improve depressive symptoms and prognosis of post-myocardial infarction and heart failure patients interacting with the common pathophysiological mechanisms of depression and cardiovascular disease. This review summarizes current experimental and clinical evidence regarding the effects of SSRIs on platelet functions, immune and neurohormonal activation, and cardiac rhythm disturbances in patients with cardiovascular disease.
Keywords: Cardiovascular disease, chronic heart failure, citalopram, coronary artery disease, dapoxetine, depression, escitalopram, fluoxetine, fluvoxamin, paroxetine, selective serotonin re-uptake inhibitors, sertraline, vilazodone
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Treating Depression in Coronary Artery Disease and Chronic Heart Failure: What’s new in using Selective Serotonin Re-Uptake Inhibitors?
Volume: 10 Issue: 2
Author(s): Paraskevaidis Ioannis, Palios John, Parissis John, Filippatos Gerasimos and Anastasiou-Nana Maria
Affiliation:
Keywords: Cardiovascular disease, chronic heart failure, citalopram, coronary artery disease, dapoxetine, depression, escitalopram, fluoxetine, fluvoxamin, paroxetine, selective serotonin re-uptake inhibitors, sertraline, vilazodone
Abstract: Depression is a common co-morbidity in patients with cardiovascular diseases such as chronic coronary artery disease, acute coronary syndromes, post by-pass surgery and chronic heart failure. The presence of depression is independently associated with a decline in health status and an increase in the risk of hospitalization and death for patients with coronary artery disease or congestive heart failure. Novel treatment modalities such as selective serotonin re-uptake inhibitors (SSRIs) may improve depressive symptoms and prognosis of post-myocardial infarction and heart failure patients interacting with the common pathophysiological mechanisms of depression and cardiovascular disease. This review summarizes current experimental and clinical evidence regarding the effects of SSRIs on platelet functions, immune and neurohormonal activation, and cardiac rhythm disturbances in patients with cardiovascular disease.
Export Options
About this article
Cite this article as:
Ioannis Paraskevaidis, John Palios, John Parissis, Gerasimos Filippatos and Maria Anastasiou-Nana, Treating Depression in Coronary Artery Disease and Chronic Heart Failure: What’s new in using Selective Serotonin Re-Uptake Inhibitors?, Cardiovascular & Hematological Agents in Medicinal Chemistry 2012; 10 (2) . https://dx.doi.org/10.2174/187152512800388894
DOI https://dx.doi.org/10.2174/187152512800388894 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Torasemide for the Treatment of Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Pharmacophore, QSAR, and Binding Mode Studies of Substrates of Human Cytochrome P450 2D6 (CYP2D6) Using Molecular Docking and Virtual Mutations and an Application to Chinese Herbal Medicine Screening
Current Pharmaceutical Biotechnology The Bleeding Risk in Antithrombotic Therapies: A Narrative Review
Current Vascular Pharmacology Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Current Pharmaceutical Design Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods
Cardiovascular & Hematological Agents in Medicinal Chemistry Integrins Modulate Cellular Fibrogenesis at Multiple Levels: Regulation of TGF-β Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets Aspartic Proteinases in Disease: A Structural Perspective
Current Drug Targets Left Ventricular Hypertrophy Beyond Hemodynamics: Genetic, Metabolic and Hormonal Factors
Current Hypertension Reviews “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Sleep in Pediatric Pulmonary Diseases
Current Respiratory Medicine Reviews Vasopressin and Oxytocin in Control of the Cardiovascular System
Current Neuropharmacology Role of NF-κB in the Regulation of Cytochrome P450 Enzymes
Current Drug Metabolism Acute Coronary Syndromes in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Effects of Thiazolidinediones Beyond Glycaemic Control
Current Pharmaceutical Design Editorial (Thematic Issue: Cell Metabolism and Current Challenges in Drug Research)
Current Pharmaceutical Design The Different Therapeutic Effects of Traditional Chinese Medicine Shensong Yangxin Capsule and Salubrinal in High-intensity Exercise-induced Heart Failure in Rats with Acute Myocardial Infarction
Combinatorial Chemistry & High Throughput Screening Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas
Anti-Cancer Agents in Medicinal Chemistry Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design Physiology and Pathophysiology of Na+/H+ Exchange Isoform 1 in the Central Nervous System
Current Neurovascular Research The Recent Trends in All-cause and Cardiovascular Mortality among People with Type 1 Diabetes Mellitus - Success is Still Far Away, and We Must Do Better!
Current Vascular Pharmacology